Clinical significance of hepatitis C virus genotypes

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 65-70

  Mondelli, Mario U ^a,b,c   Silini, Enrico ^a,b,c  

^a Ist di Clin delle Malat Infettive   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiviral therapy; Genotypes; Hepatitis C virus; Hepatocellular carcinoma; Histology; Intravenous drug users; Liver disease

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

CONFERENCE PAPER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VIRUS CHARACTERIZATION; VIRUS CLASSIFICATION;

EID: 0033404626     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80377-8     Document Type: Conference Paper

References (85)

1. Simmonds P. Variability of hepatitis C virus. Hepatology 1995: 21: 570-583.
2. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992: 73: 673-679.
3. Ohno O, Mizokami M, Wu RR, Saleh MG, Ohba K, Orito E et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes la, Ib, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997: 35: 201-207.
4. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van HH et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993:74:1093-1102.
5. Davidson F, Simmonds P, Ferguson JC et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol 1995:76:1197-1204.
6. Mondelli MU, Cerino A, Bono F, Cividini A, Malfitano A, Maccabruni A et al. Hepatitis C virus (HCV) core serotypes in chronic HCV infection. J Clin Microbiol 1994: 32: 2523-2527.
7. Machida A, Ohnuma H, Tsuda F, Munekata E, Tanaka T, Akahane Y et al. Two distinct subtypes of hepatitis C virus defined by antibodies directed to the putative core protein. Hepatology 1992: 16: 886-891.
8. Bhattacherjee V, Prescott LE, Pike I, Rodgers B, Bell H, EI-Zayadi AR et al. Use of NS-4 peptides to identify type-specific antibody to genotypes 1, 2, 3,4, 5 and 6. J Gen Virol 1995: 76: 17371748.
9. Lau JYN, Mizokami M, Kolberg JA, Davis GL, Prescott LE, Ohno T et al. Applications of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995: 171: 281-289.
10. Cerino A, Cividini A, Asti M, Lanza A, Silini E, Mondelli MU. Comparative evaluation of two sérologie typing methods of hepatitis C virus. J Clin Microbiol 1996: 34: 714-716.
11. Pawlotski JM, Prescott L, Simmonds P, Pellet C, Laurent-Puig P, Labonne C et al. Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. J Clin Microbiol 1997: 35: 1734-1739.
12. McOmish F, Yap PL, Dow BC et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994: 32: 884-892.
13. Silini E, Mondelli MU. Significance of hepatitis C virus genotypes. Viral Hepat Rev 1995: 1: 111-120.
14. Mahaney K, Tedeschi V, Maertens G, Di Bisceglie AM, Vergalla J, Hoofnagle JH et al. Genotypic analysis of hepatitis C virus in American patients. Hepatology 1994: 20: 1405-1411.
15. McOmish F, Chan SW, Dow BC et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in sérologie reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993: 33: 7-13.
16. Nousbaum J-B, Pol S, Nalpas B, Landais P, Berthelot P, Bréchot C, Group at CS. Hepatitis C virus type Ib (II) infection in France and Italy. Ann Intern Med 1995: 122: 161-168.
17. Viazov S, Kuzin S, Paladi N, Tchernovetsky M, Isaeva E, Mazhul L et al. Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol 1997: 53: 36-10.
18. Puoti C, Magrini A, Stati T, Rigato P, Montagnese F, Rossi P et al. Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels. Hepatology 1997: 26: 1393-1398.
19. Guadagnino V, Stroffolini T, Rapicetta M, Costantino A, Kondili LA, Menniti-Ippolito F et al. Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy. Hepatology 1997: 26: 1006-1011.
20. Osella AR, Sonzogni L, Cavallini A, Foti L, Guerra V, Di Leo A, Mondelli MU, Misciagna G, Silini EM. Molecular epidemiology 'of hepatitis C virus infection in an area of hyperendemicity in Southern Italy: a population-based study. J Clin Microbiol 1999: 37: 2371-2372.
21. Silini EM, Bono F, Cividini A et al. Molecular epidemiology of hepatitis C virus infection among intravenous drug users. J Hepatol 1995: 22: 691-695.
22. Pol S, Thiers V, Nousbaum J-B, Legendre C, Berthelot P, Kreis H et al. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995: 108: 581-583.
23. Pawlotsky JM, Tsakiris L, Roudot-Thoraval F, Pellet C, Stuyver L, Duval J et al. Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C. J Infect Dis 1995: 171: 1607-1610.
24. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative El gene of isolates collected worldwide. Proc Natl Acad Sci USA 1993: 90: 8234-8238.
25. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G et al. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. J Gen Virol 1993: 74: 661-668.
26. Zehender G, de Maddalena C, Monti G, Ballarè M, Saccardo F, Piconi S et al. HCV genotypes in bone marrow and peripheral blood mononuclear cells of patients with mixed cryoglobulinaemia. Clin Exp Rheumatol 1995: 13: S87-S90.
27. Andreone P, Zignego AL, Cursaro C, Gramenzi A, Gherlinzoni F, Fiorino S et al. Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection. Ann Intern Med 1998: 129: 294-298.
28. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol 1996: 25: 427-432.
29. Silvestri F, Pipan C, Barillari G, Zaja F, Fanin R, Infant! L et al. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders. Blood 1996: 87: 4296-301.
30. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P et al. Morbidity and mortality in compensated cirrhosis C: a retrospective study of 384 patients. Gastroenteroloay 1997: 112:46272.
31. Pozzato G, Kaneko S, Moretti M et al. Different genotypes of hepatitis C virus are associated with different severity of chronic liver disease. J Med Virol 1994: 43: 291-296.
32. Mita E, Hayashi N, Kanazawa Y, Hagiwara H, Ueda K, Kasahara A et al. Hepatitis C virus genotype and RNA titer in the progression of type C chronic liver disease. J Hepatol 1994: 21: 46873.
33. Cathomas G, McGandy CE, Terracciano LM, Gudat F, Bianchi L. Detection and typing of hepatitis C RNA in liver biopsies and its relation to histopathology. Virchows Arch 1996:429: 353-358.
34. Zein NN, Poterucha JJ, Gross JB Jr, Wiesner RH, Therneau TM, Gossard AA et al. Increased risk of hepatocellular carcinoma in patients infected with hepatitis C genotype Ib. Am J Gastroenterol 1996: 91: 2560-2562.
35. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Parsing DH. Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to Interferon therapy. Collaborative Study Group. Ann Intern Med 1996: 125: 634-639.
36. Booth JC, Foster GR, Levine T, Thomas HC, Goldin RD. The relationship of histology to genotype in chronic HCV infection. Liver 1997: 17: 144-151.
37. Naoumov NV, Chokshi S, Metivier E, Maertens G, Johnson PJ, Williams R. Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. J Hepatol 1997: 27: 331336.
38. Mangia A, Cascavilla I, Lezzi G, Spirito F, Maertens G, Parlatore L et al. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 1997: 26: 1173-1178.
39. Guido M, Rugge M, Thung SN, Chemello L, Leandro G, Alberti A et al. Hepatitis C virus serotypes and liver pathology. Liver 1996: 16: 353-357.
40. Ravaggi A, Rossini A, Mazza C, Puoti M, Marin MG, Cariani E. Hepatitis C virus genotypes in northern Italy: clinical and virological features. J Clin Microbiol 1996: 34: 2822-2825.
41. Lee DS, Sung YC, Whang YS. Distribution of HCV genotypes among blood donors, patients with chronic liver disease, hepatocellular carcinoma, and patients on maintenance hemodialysis in Korea. J Med Virol 1996: 49: 55-60. Silini EM, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995: 21: 285-290.
42. Yotsuyanagi H, Koike K, Yasuda K, Moriya K, Hino K, Kurokawa K et al. Hepatitis C virus genotypes and hepatocellular carcinoma. Cancer 1995: 76: 1352-1355.
43. Kleter B, Brouwer JT, Nevens F, van Doom LJ, Elewaut A, Versieck J et al. Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux Study Group on Treatment of Chronic Hepatitis C. Liver 1998: 18: 32-38.
44. Silini EM, Bono F, Cividini A et al. Differential distribution of hepatitis C virus genotypes in patients with and without liver function abnormalities. Hepatology 1995: 21: 285-290.
45. Prati D, Capelli C, Zanella A, Mozzi F, Bosoni P, Pappalettera M et al. Influence of different hepatitis C virus genotypes on the course of asymtomatic hepatitis C voris infection. Gastroenterology 1996: 110: 178-183.
46. Rossini A, Ravaggi A, Agostinelli E, Bereich L, Gazzola GB, Radaeli E et al. Virological characterization and liver histology in HCV positive subjects with normal and elevated ALT. Liver 1997: 17: 133-138.
47. Silini E, Bottelli R, Asti M, Bruno S, Candusso ME, Brambilla S et ai. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996: 111: 199-205.
48. Hatzakis A, Katsoulidou A, Kaklamani E, Touloumi G, Koumantaki Y, Tassopoulos NC et al. Hepatitis C virus Ib is the dominant genotype in HCV-related carcinogenesis: a case-control study. Int J Cancer 1996: 68: 51-53.
49. Donato F, Tagger A, Chiesa R, Ribero ML, Tomasoni V, Fasola M et al. for the Brescia HCC Study. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: a casecontrol study in Italy. Hepatology 1997: 26: 579-584.
50. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C: a comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996: 23: 695-699.
51. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997: 25: 754.
52. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995: 21: 650655.
53. Benvegnu L, Pontisso P, Cavalletto D, Noventa F, Chemello L, Alberti A. Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis. Hepatology 1997: 25: 211-215.
54. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998: 27: 1435-1440.
55. Féray C, Gigou M, Samuel D et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995: 108: 1088-1096.
56. Caccamo L, Gridelli B, Sampietro M, Melada E, Doglia M, Lunghi G et al. Hepatitis C virus genotypes and reinfection of the graft during long-term follow-up in 35 liver transplant recipients. Transpl Int 1996: 9: S204-209.
57. Belli LS, Silini E, Alberti A, Bellati G, Vai C, Minola Eet al. Hepatitis C virus genotypes, hepatitis, and hepatitis C virus recurrence after liver transplantation. Liver Transpl Surg 1996: 2: 200-205.
58. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996: 34: 815-820.
59. Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB Jr et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997: 63: 1419-1423.
60. Gayowski T, Singh N, Marino IR, Vargas H, Wagener M, Wannstedt C et al. Hepatitis C virus genotypes in liver transplant recipients: impact on posttransplant recurrence, infections, response to interferon-alpha therapy and outcome. Transplantation 1997: 64: 422-426.
61. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996: 24: 1041-1046.
62. Vargas HE, Laskus T, Wang LF, Radkowski M, Poutous A, Lee R et al. The influence of hepatitis C virus genotypes on the outcome of liver transplantation. Liver Transpl Surg 1998: 4: 22-27.
63. Cacciola I, Pollicino T, Squadrito G, Carenzia G, Orlando ME, Raimondo G. Occult HBV infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999: in press.
64. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C et al. the Multicenter Study Group. A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic Non-A, Non-B hepatitis. N Engl J Med 1995: 332: 1457-1462.
65. Chemello L, Cavalletto L, Donada C, Bonetti P, Casarin P, Urban F et al. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Gastroenterology 1997: 113: 1654-1659.
66. Bellobuono A, Mondazzi L, Tempini S, Silini E, Ideo G. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis for factors predictive of sustained response to treatment. Eur J Gastroenterol Hepatol 1997: 12: 1169-1177.
67. Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alpha-n 1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alpha-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 1998: 27: 1121-1127.
68. Pawlotsky JM, Germanidis G, Neumann AU, Pellerin M, Frainais PO, Dhumeaux D. Interferon resistance of hepatitis C virus genotype Ib: relationship to nonstructural 5A gene quasispecies mutations. J Virol 1998: 72: 2795-2805.
69. Brouwer JT, Nevens F, Kieler B, Elewaut A, Adler M, Brenard R et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. J Hepatol 1998: 28: 951-959.
70. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnenborg A, Weiland O. Randomised, double blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998: 351: 8387.
71. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon alpha 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998: 352: 1426-1432.
72. Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: relationship to genotypes of hepatitis C virus. Hepatology 1992: 16: 293299.
73. Orito E, Mizokami M, Mizoguchi N, Ohba K, Tohnai M, Yamanaka H et al. Hepatitis C virus serotype II responds more favorably to interferon-alpha therapy. J Hepatol 1994: 21: 130-132.
74. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994: 39: 977982.
75. Matsumoto A, Tanaka E, Suzuki T, Ogata H, Kiyosawa K. Viral and host factors that contribute to the efficacy on interferonalpha 2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994: 39: 1273-1280.
76. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S et al. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection. Hepatology 1994: 19: 1088-1094.
77. Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatoloay 1995: 22: l OSO1056.
78. Yuki N, Hayashi N, Mita E, Hagiwara H, Oshita M, Ohkawa K et al. Clinical characteristics and antibody profiles of chronic hepatitis C patients: relation to hepatitis C virus genotypes. J Med Virol 1995: 45: 162-167.
79. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P et al. Randomized trial comparing three different regimens of alpha 2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatolology 1995: 22: 700-706.
80. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Baiart LA, Dienstag JL et al. Response to higher doses of interferon alpha2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996: 24: 1034-1040.
81. Mizokami M, Orito E, Gibo Y, Suzuki K, Ohba K, Ohno T et al. Genotype, serum level of hepatitis C virus RNA and liver histology as predictors of response to interferon-alpha 2a therapy in Japanese patients with chronic hepatitis C. Liver 1996: 16: 2327.
82. Hopf U, Berg T, König V, Küther S, Heuft HG, Lobeck H. Treatment of chronic hepatitis C with interferon alpha: long-term follow-up and prognostic relevance of HCV genotypes. J Hepatol 1996: 24: 67-73.
83. McHutchison JG, Gordon ST, Schiff ER, Shiffmann ML, Lee WM, Rustgi VK et al. For the Hepatitis Interventional Therapy Group. Interferon Alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998: 339: 1485-1492.
84. Davis GL, Mur RE, Rustgi V, Hoefs J, Gordon SC, Trepo C et al. For the Hepatitis Interventional Therapy Group. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N End J Med 1998: 339: 14931499.
85. Liang TJ. Combination therapy for hepatitis C infection. N Engl J Med 1998: 339: 1549-1550.